{
  "pmcid": "10364680",
  "sha256": "5fd83d75061b7afa2644096bf92d8a22e1a12a94dd8d18e45ee0c08e05689fdc",
  "timestamp_utc": "2025-11-09T15:06:58.848086+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 12.25385148918809,
    "reading_ease": 31.394228886168946,
    "word_count": 258
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Data from a multicentre, double-blind, randomized placebo-controlled superiority trial were used."
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Patients scheduled for laparoscopic RYGB or sleeve gastrectomy were randomized to receive 900 mg UDCA or placebo for 6 months."
      },
      "Participants": {
        "score": 1,
        "evidence": "Patients scheduled for laparoscopic RYGB or sleeve gastrectomy were randomized."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients scheduled for laparoscopic RYGB or sleeve gastrectomy were randomized to receive 900 mg UDCA or placebo for 6 months."
      },
      "Objective": {
        "score": 1,
        "evidence": "The aim was to evaluate the cost-effectiveness and cost–utility of ursodeoxycholic acid (UDCA) prophylaxis for the prevention of symptomatic gallstone disease after Roux-en- Y gastric bypass (RYGB) in patients without gallstones before surgery."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "Main outcomes were the costs per patient free from symptomatic gallstone disease and the costs per quality-adjusted life-year (QALY)."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 3,
        "evidence": "Data from a multicentre, double-blind, randomized placebo-controlled superiority trial were used."
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Patients receiving UDCA prophylaxis were more likely to remain free from symptomatic gallstone disease (relative risk 1.06, 95 per cent c.i. 1.02 to 1.11; P = 0.002) compared with patients in the placebo group."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}